CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
Category: #health  By Mateen Dalal  Date: 2020-02-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various solid tumor cancers, such as brain-glioblastoma, melanoma, throat, stomach, lung, colon carcinoma, testicular, breast, ovarian, pancreas, uterine, bladder, among other indications. It is expecting to obtain preliminary outcomes on each subject within 3 to 4 weeks after the initial medication with leronlimab.  CytoDyn will continue to register patients in its metastatic breast cancer studies. 

The basket trial is a Phase 2 study with CCR5+ locally advanced or metastatic solid tumors including 30 subjects. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg. Patients partaking in the trial will be allowed to receive and continue the standard-of-care chemotherapy as defined by the treating physician.

Bruce Patterson, M.D., Founder and Chief Executive Officer, IncellDx, an advisor and a diagnostic partner to CytoDyn, reportedly stated that the outcomes in patients with breast cancer have shown reduction in primary tumors, decrease in CTCs to zero, elimination or shrinking of metastatic lesions and remained stable for several weeks. Other trials demonstrated CTC levels in this cancer >5 and some as high as 20 per 4 mL of blood, he added.

Nader Pourhassan, Ph.D., Chief Executive Officer and President, CytoDyn, reportedly stated that if leronlimab  is able to demonstrate efficacy in this basket trial as the company has observed in the first 4 subjects in its MBC trials, the company will be able to file for another innovative therapy designation (BTD) for the multiple cancer indications evaluated in this study. Since the company started its cancer trials for mTNBC and compassionate usage and extended access for MBC, it has been receiving requests from subjects in the U.S. and overseas, he further added.

Source links:

https://www.cytodyn.com/newsroom/press-releases/detail/382/cytodyn-files-a-phase-2-basket-trial-with-leronlimab-pro

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NHS requests urgent donations of blood plasma from COVID-19 survivors
NHS requests urgent donations of blood plasma from COVID-19 survivors
By Mateen Dalal

According to reliable sources, United Kingdom National Health Service (NHS) has filed an appeal to the individuals recuperated from novel coronavirus to donate blood plasma. The organization apparently intends to treat the people who get infected dur...

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
By Mateen Dalal

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19....

Singapore’s ESR and Sabana REIT propose merger amid pandemic
Singapore’s ESR and Sabana REIT propose merger amid pandemic
By Mateen Dalal

Although the economic impact of the ongoing COVID-19 has significantly impacted prospects for Singapores REITs (Real Estate Investment Trusts), it seems that some resilient spots in the real estate sector will remain where they were. In the latest st...